Yazar "Bitirgen G." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Surgical outcomes of Ex-PRESS® mini glaucoma shunt implantation [Ex-PRESS® mini glokom İmplant cerrahisi sonuçlarımız]
    (Turkiye Klinikleri, 2014) Okka M.; Bitirgen G.; Kerimoğlu H.; Bozkurt B.; Yumak Erkoça H.
    Objective: To evaluate intraocular pressure (IOP) lowering effect and safety of Ex-PRESS® mini glaucoma drainage implant (Alcon, Fort Worth, TX) for the surgical treatment of glaucoma. Material and Methods: The data of the subjects who underwent Ex-PRESS® mini glaucoma shunt (P-50) implantation surgery in 2011 and 2012 were retrospectively reviewed. IOP before and after the treatment, visual acuity, the number of medications and complications were analyzed. Success was defined as final IOP of 6-21 mmHg with or without antiglaucomatous medications. Results: Thirty two eyes of 32 patients were included in the study. The mean age of patients and mean follow-up time were 54.43±14.56 years (range 20-77 years) and 6.34±2.95 months (range 3-16 months), respectively. Mean pretreatment IOP was 30.71±4.72 mmHg, while it was 13.21±3.51 mmHg (p<0.001) at the first week, 14.46±4.08 mmHg (p<0.001) in the first month, 14.37±2.93 mmHg (p<0.001) in the third month, 13.78±2.98 mmHg (p<0.001) in the sixth month, and 14.53±2.27 mmHg (p<0.001) in the last visit. An IOP less than 21 mmHg was achieved in all eyes in the last visit. The median value of preoperative total antiglaucomatous medications was 4.0 (3.0-5.0), however topical medications were discontinued in 81.3% of patients in the last visit. There were no complications during the follow-up period except one case of early postoperative choroidal effusion. Conclusion: Ex-PRESS® mini glaucoma shunt implantation is supposed to be an effective and safe method for the surgical treatment of glaucoma. It also helped to reduce the number of antiglaucoma medications, thus improving both the quality of life of the patients and their compliance to therapy. © 2014 by Türkiye Klinikleri.
  • Küçük Resim Yok
    Öğe
    Transscleral diode laser cyclophotocoagulation in refractory glaucoma [Dirençli glokom olgularında transskleral diod lazer siklofotokoagülasyon]
    (Turkish Ophthalmology Society, 2013) Bitirgen G.; Okka M.; Bozkurt B.; Do?ru I.; Kerimo?lu H.; Öztürk B.T.; Kamiş U.
    Purpose: To evaluate the safety and efficacy of transscleral diode laser cyclophotocoagulation (TSDLC) in advanced glaucoma refractory to medical or surgical treatment. Material and Method: The data of subjects who were treated with TSDLC between 2009 and 2011 were retrospectively reviewed. Intraocular pressure before and after treatment, visual acuity, the number of medications and complications were analysed. Success was defined as final IOP of 6-22 mmHg with or without antiglaucomatous medications. Results: Thirty seven eyes of 37 patients were included in the study. Mean age of patients and mean follow-up time were 61.73±17.13 years (range: 19-80 years) and 8.06±5.81 months (range: 3-22 months), respectively. Mean pretreatment IOP was 38.68±8.94 mmHg and IOP was 26.46±11.34 mmHg (p <0.01) at the second week, whereas it was 24.97±10.84 mmHg (p<0.01) at the last visit. IOP of less than 22 mmHg was achieved in 40.5% of eyes at the last visit. Mean treatment number per eye was 1.48±0.73, and more than one treatment was required in 13 (35.1%) eyes. Preoperative and postoperative mean total antiglaucomatous medications were 3.14±1.18 and 2.76±1.23, respectively. No phthisis bulbi or persistent hypotonia developed during the follow-up period. Discussion: TSDLC is an effective and safe method for the treatment of refractory glaucoma. It also served to reduce the number of antiglaucoma medications, thus improving both the quality of life of the patients and their compliance to therapy. © Galenos Yayinevi.